DexCom (DXCM) Given Daily News Impact Rating of 0.22

News coverage about DexCom (NASDAQ:DXCM) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DexCom earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 46.3687510778926 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

DexCom (NASDAQ DXCM) traded down $0.06 on Wednesday, hitting $56.88. 625,962 shares of the stock were exchanged, compared to its average volume of 1,442,857. The stock has a market cap of $4,950.00, a price-to-earnings ratio of -99.79 and a beta of 0.30. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom has a 12-month low of $42.62 and a 12-month high of $88.80.

A number of research analysts recently weighed in on the stock. BidaskClub lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Jefferies Group lifted their price objective on shares of DexCom from $58.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. BMO Capital Markets lifted their price objective on shares of DexCom to $74.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. Finally, Morgan Stanley reduced their price objective on shares of DexCom from $72.00 to $52.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company’s stock. DexCom has an average rating of “Buy” and an average target price of $70.19.

In other DexCom news, Director Steven R. Altman purchased 10,000 shares of the stock in a transaction on Monday, November 6th. The stock was acquired at an average cost of $49.61 per share, with a total value of $496,100.00. Following the completion of the purchase, the director now directly owns 4,353 shares of the company’s stock, valued at approximately $215,952.33. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 12,000 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $55.00, for a total transaction of $660,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,505 shares of company stock valued at $2,066,379 over the last ninety days. 1.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “DexCom (DXCM) Given Daily News Impact Rating of 0.22” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://weekherald.com/2017/12/27/dexcom-dxcm-given-daily-news-impact-rating-of-0-22.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply